Perrone, E.; Ghai, K.; Eismant, A.; Andreassen, M.; Langer, S.W.; Knigge, U.; Kjaer, A.; Baum, R.P.
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with 177Lu/225AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas. Diagnostics 2024, 14, 907.
https://doi.org/10.3390/diagnostics14090907
AMA Style
Perrone E, Ghai K, Eismant A, Andreassen M, Langer SW, Knigge U, Kjaer A, Baum RP.
Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with 177Lu/225AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas. Diagnostics. 2024; 14(9):907.
https://doi.org/10.3390/diagnostics14090907
Chicago/Turabian Style
Perrone, Elisabetta, Kriti Ghai, Aleksandr Eismant, Mikkel Andreassen, Seppo W. Langer, Ulrich Knigge, Andreas Kjaer, and Richard P. Baum.
2024. "Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with 177Lu/225AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas" Diagnostics 14, no. 9: 907.
https://doi.org/10.3390/diagnostics14090907
APA Style
Perrone, E., Ghai, K., Eismant, A., Andreassen, M., Langer, S. W., Knigge, U., Kjaer, A., & Baum, R. P.
(2024). Impressive Response to TANDEM Peptide Receptor Radionuclide Therapy with 177Lu/225AcDOTA-LM3 Somatostatin Receptor Antagonist in a Patient with Therapy-Refractory, Rapidly Progressive Neuroendocrine Neoplasm of the Pancreas. Diagnostics, 14(9), 907.
https://doi.org/10.3390/diagnostics14090907
